Management of skin metastases of ovarian cancer: a novel therapeutic approach.

Strahlenther OnkolMay 13, 2026 (epub)
Case ReportOncology (Medical)DermatologyOpen access

Anne-Marie Lüchtenborg, Jörg Sahlmann, Kristin Technau-Hafsi et al.

✦ AI-curated · Sources linked

Case in brief

A woman with extensive skin metastases from high-grade serous ovarian carcinoma on her thigh was treated with a novel combination therapy. This included mild hyperthermia (39-43 °C) followed by low-dose hypofractionated radiotherapy and systemic chemotherapy with carboplatin and gemcitabine. The patient showed a positive response and remained tumor-free in the treated area for over 1 year.

Diagnostic / clinical pearl

The combination of mild hyperthermia with radiotherapy and systemic chemotherapy may effectively control skin metastases in ovarian cancer, even with reduced radiation doses.

Why it matters

This case highlights a potential new therapeutic approach for managing skin metastases, which could be applicable to other malignancies as well.

Source

PubMed · PMID 42126534Free full text on PubMed Central

Published in Strahlenther Onkol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.